NSD2 and osteosarcoma: This finding was inconsistent with previous studies, which manifested that Nsd2 deletion reduced H3K36me2 levels in prostate cancer,[20, 21] breast cancer,[22] osteosarcoma,[23] lung adenocarcinoma,[24] etc. The maintained H3K36me2 level could be elucidated by the fact that the expression levels of demethylases of the H3K36 site, including Kdm2b, Kdm4a, Kdm4b, and No66, were also significantly decreased in the Nsd2‐deficient pancreas, and the expression level of Nsd3 was significantly increased, while Nsd1 expression remained unchanged (Figure 2C).